The Coronavirus disease 2019 (COVID-19) pandemic has led to many ICU admissions sharing a similar pathology with a high incidence of neurological sequelae, such as delirium and ischaemic stroke.4–8 This provided an opportunity to study NfL and it’s relation to clinical and biochemical parameters using repeated sampling in a well-characterized group of patients in order to explore the dynamics of NfL and whether it could function as a prognostic marker for neurological dysfunction. The gene discussed is NEFL; the disease is COVID-19.